Atlas Trials

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Clinical trial NCT03807063 · WITHDRAWN

Trial details

NCT number
NCT03807063
Sponsor
Fred Hutchinson Cancer Center
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Bilineal LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyeloproliferative NeoplasmRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome
Start date
2020-01-02
Primary completion
2020-12-31
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.